Exelixis (NASDAQ: EXEL) recently received a number of ratings updates from brokerages and research firms:

  • 9/20/2016 – Exelixis had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $12.00 price target on the stock.
  • 9/15/2016 – Exelixis had its “outperform” rating reaffirmed by analysts at William Blair.
  • 9/15/2016 – Exelixis had its price target raised by analysts at Stifel Nicolaus from $12.00 to $15.00. They now have a “buy” rating on the stock.
  • 9/13/2016 – Exelixis was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $14.00 price target on the stock. According to Zacks, “Exelixis received a major boost with the FDA approval of Cabometyx. It is currently focused on launching Cabometyx tablets as a treatment for patients with advanced RCC. Initial uptake of the drug was encouraging and will propel the top line in the forthcoming quarters. Meanwhile, the European Medicines Agency has also accepted a Marketing Authorisation Application (MAA) for Cabometyx for review in the same indication. Upon a potential approval, the product will be marketed in the EU by Exelixis’ partner, Ipsen. Exelixis is developing cabozantinib in a broad development program comprising over 45 clinical studies across multiple indications. Moreover, successful commercialization of other drug, Cotellic in the U.S. will boost the top line. However, expenses are expected to increase as the company prepares for the commercialization of Cabometyx in the U.S.”
  • 9/7/2016 – Exelixis had its “positive” rating reaffirmed by analysts at Leerink Swann. They now have a $12.00 price target on the stock.
  • 8/29/2016 – Exelixis had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $12.00 price target on the stock.
  • 8/18/2016 – Exelixis had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $12.00 price target on the stock.
  • 8/10/2016 – Exelixis had its “buy” rating reaffirmed by analysts at Cowen and Company.
  • 8/4/2016 – Exelixis had its price target raised by analysts at Stifel Nicolaus from $10.00 to $12.00. They now have a “buy” rating on the stock.
  • 8/4/2016 – Exelixis had its “neutral” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $8.00 price target on the stock, up previously from $5.00.
  • 8/4/2016 – Exelixis had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $12.00 price target on the stock, up previously from $10.00.

Exelixis Inc. (NASDAQ:EXEL) traded up 1.3835% during mid-day trading on Wednesday, reaching $14.3559. 4,524,305 shares of the company traded hands. The stock’s 50 day moving average price is $11.45 and its 200 day moving average price is $7.38. The firm’s market capitalization is $3.31 billion. Exelixis Inc. has a 52 week low of $3.55 and a 52 week high of $14.95.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.11. The company had revenue of $36.25 million for the quarter, compared to analysts’ expectations of $16.76 million. The firm’s quarterly revenue was up 353.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.22) EPS. Equities analysts forecast that Exelixis Inc. will post ($0.63) EPS for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/research-analysts-weekly-ratings-changes-for-exelixis-exel.html

In other news, insider Gisela Schwab sold 42,338 shares of the business’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $11.00, for a total transaction of $465,718.00. Following the completion of the sale, the insider now owns 174,354 shares in the company, valued at approximately $1,917,894. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.90% of the company’s stock.

Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.

5 Day Chart for NASDAQ:EXEL

Receive News & Ratings for Exelixis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc and related companies with MarketBeat.com's FREE daily email newsletter.